ODG
REGN icon

O'Dell Group’s Regeneron Pharmaceuticals REGN Stock Holding History

O'Dell Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31
Closed -$27.2K – 387
2023
Q4 		$27.2K Buy
+31
New +$25.5K 0.01% 265
2023
Q3 		– Sell
-31
Closed -$22.3K – 382
2023
Q2 		$22.3K Buy
+31
New +$23.9K 0.01% 270
2022
Q4 		– Sell
-31
Closed -$21K – 321
2022
Q3 		$21K Hold
31
– – 0.01% 225
2022
Q2 		$18K Hold
31
– – 0.01% 238
2022
Q1 		$22K Hold
31
– – 0.01% 248
2021
Q4 		$20K Hold
31
– – 0.01% 239
2021
Q3 		$19K Buy
+31
New +$19.2K 0.01% 240

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

O'Dell Group's REGN Position: Q1 2024 in Review

O'Dell Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 31 shares — an estimated $27.2K sold.

O'Dell Group first reported a position in REGN in Q3 2021 and held it in 7 quarters. The position peaked at $27.2K in Q4 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • O'Dell Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • O'Dell Group sold 31 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $27.2K.
  • O'Dell Group first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • O'Dell Group's Regeneron Pharmaceuticals position peaked at $27.2K in Q4 2023.
  • 1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.